Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
Key facts
- Who runs it
- Sanofi
- Where
- Westwood, United StatesSee the siteAlso in 7 other countries, 21 sites
- Trial code
- NCT04524689
- EudraCT 2023-509115-84
- U1111-1233-9798
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 57 people enrolled
- Started
- 26 Oct 2020
- Ended
- 24 Dec 2024
- Type of study
- Interventional, 6 groups
- Treatments tested
- SAR408701 (Tusamitamab ravtansine)
- Pembrolizumab
- Cisplatin
- Carboplatin
- Pemetrexed
- Record updated
- 29 October 2025
- Why it stopped
- Sponsor decision, the decision is not related to any safety concern.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- Histologically- or cytologically-confirmed diagnosis of advanced or metastatic NSQ NSCLC with no EGFR sensitizing mutation or BRAF mutation or ALK/ROS alterations
- No prior systemic chemotherapy for the treatment of the participant's advanced or metastatic disease (treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as completed at least 6 months prior to diagnosis of advanced or metastatic disease)
- Expression of CEACAM5 as demonstrated prospectively by a centrally assessed Immunohistochemistry (IHC) assay of ≥2+ in intensity involving at least 1% of the tumor cell population in archival tumor sample (or if not available fresh biopsy sample)
- Measurable disease based on RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- Life expectancy of at least 3 months
Who cannot take part
- Medical condition requiring concomitant administration of a medication with a strong CYP3A inhibitor
- Significant concomitant illness, including any severe medical condition that, in the opinion of the investigator or Sponsor, would impair the patient's participation in the study or interpretation of the results
- Active infection requiring IV systemic therapy within 2 weeks prior to randomization or active tuberculosis
- Non-resolution of any prior treatment-related toxicity to < Grade 2 according to NCI CTCAE V5.0, with the exception of alopecia, vitiligo, or active thyroiditis controlled with hormone replacement therapy
- Unresolved corneal disorder or any previous corneal disorder considered by an ophthalmologist to predict higher risk of drug-induced keratopathy. The use of contact lenses is not permitted
- Symptomatic herpes zoster within 3 months prior to screening
- Concurrent treatment with any other anticancer therapy
- Have received prior chemotherapy treatment for advanced/metastatic NSCLC
- The patient is a candidate for a curative treatment with either surgical resection and/or chemoradiation
- Washout period before the first administration of study intervention of less than 3 weeks or less than 5 times the half-life, whichever is shorter, for any investigational treatment)
- Any prior therapy targeting CEACAM5
- Any prior maytansinoid treatment (DM1 or DM4 ADC)
- Is receiving systemic steroid therapy ≤3 days prior to the first dose of study therapy or receiving any other form of immunosuppressive medication. Daily steroid replacement therapy or any corticosteroid premedication if applicable are allowed
- Any radiation therapy to lung >30 Gy within 6 months of first study intervention administration
- Has received or will receive a live vaccine within 30 days prior to the first study intervention administration
- Any major surgery within the preceding 3 weeks of the first study intervention administration; Prior/concurrent clinical study experience
- Uncontrolled brain metastases and history of leptomeningeal disease
- History within the last 3 years of an invasive malignancy other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment
- History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known HIV disease requiring antiretroviral treatment, or active hepatitis A, B, or C infection
- History of active autoimmune disease that has required systemic treatment in the past 2 years
- History of allogeneic tissue/solid organ transplantation
- Interstitial lung disease or history of pneumonitis that has required oral or IV steroids
- Significant allergies to humanized monoclonal antibodies
- Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A [IgA] dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis)
- Any prior treatment with any other anti-PD-1, or PD-L1 or programmed death ligand 2 (PD-L2), anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4
- Current participation in any other clinical study involving an investigational study treatment or any other type of medical research
- Poor organ function; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Where in United States
Also in 7 other countries, 21 sites
- KU Medical Center_Investigational Site Number :8400002Westwood, United States
About the trial
What the trial wants to find out
Primary Objective:
Read full original descriptionShow less
* Safety run-in part: to assess the tolerability and to determine the recommended doses of tusamitamab ravtansine in combination with pembrolizumab and tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy with or without pemetrexed to be tested in the expansion part of the study in the NSQ NSCLC population * Expansion part (including participants treated at the recommended dose for expansion [RDE] from the Safety Run-in part): to assess the antitumor activity of several dose levels (DLs; if applicable) of tusamitamab ravtansine in combination with pembrolizumab and of several DLs of tusamitamab ravtansine in combination with pembrolizumab, platinum-based chemotherapy, and pemetrexed in the NSQ NSCLC population
Secondary Objectives:
* To assess the safety and tolerability of several DLs (if applicable) of tusamitamab ravtansine in combination with pembrolizumab and of 1 DL of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy, and of several DLs of tusamitamab ravtansine in combination with pembrolizumab, and platinum-based chemotherapy with pemetrexed in the NSQ NSCLC population * To assess the antitumor activity of several DLs (if applicable) of tusamitamab ravtansine in combination with pembrolizumab and of 1 DL of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy, and of several DLs of tusamitamab ravtansine in combination with pembrolizumab, platinum-based chemotherapy, and pemetrexed in the NSQ NSCLC population * To assess the durability of the response to treatment with several DLs (if applicable) of tusamitamab ravtansine in combination with pembrolizumab and of 1 DL of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy, and of several DLs of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy, and pemetrexed in the NSQ NSCLC population * To assess the antitumor activity of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy in the NSQ NSCLC population * To assess the pharmacokinetics (PK) of tusamitamab ravtansine, pembrolizumab, pemetrexed, cisplatin, and carboplatin, each when given in combination as a doublet (tusamitamab ravtansine + pembrolizumab) or a triplet (tusamitamab ravtansine + pembrolizumab + platinum-based chemotherapy) or a quadruplet (tusamitamab ravtansine + pembrolizumab + platinum-based chemotherapy + pemetrexed) * To assess the immunogenicity of tusamitamab ravtansine in combination with pembrolizumab and tusamitamab ravtansine in combination with pembrolizumab and platinum based chemotherapy with or without pemetrexed
The 6 groups in the trial
- Tusamitamab ravtasine 150 mg/m^2 + PembrolizumabTreatment being tested
Pembrolizumab dose will be administered intravenously prior to intravenous administration of tusamitamab ravtansine dose every 3 weeks.
Treatment: SAR408701 (Tusamitamab ravtansine) and Pembrolizumab
- Tusamitamab ravtasine 170 mg/m^2 + PembrolizumabTreatment being tested
Pembrolizumab dose will be administered intravenously prior to intravenous administration of tusamitamab ravtansine dose every 3 weeks.
Treatment: SAR408701 (Tusamitamab ravtansine) and Pembrolizumab
- Tusamitamab ravtansine 150 mg/m^2 + Pembrolizumab + carboplatin or cisplatinTreatment being tested
Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Carboplatin will be infused over 15 to 60 minutes immediately after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.
Treatment: SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, and Carboplatin
- Tusamitamab ravtansine 170 mg/m^2 + Pembrolizumab + carboplatin or cisplatinTreatment being tested
Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Carboplatin will be infused over 15 to 60 minutes immediately after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.
Treatment: SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, and Carboplatin
- Tusamitamab ravtansine 150 mg/m^2 + Pembrolizumab + carboplatin or cisplatin + pemetrexedTreatment being tested
Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Carboplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after pemetrexed infusion after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.
Treatment: SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, Carboplatin, and Pemetrexed
- Tusamitamab ravtansine 170 mg/m^2 + Pembrolizumab + carboplatin or cisplatin + pemetrexedTreatment being tested
Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Carboplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after pemetrexed infusion after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.
Treatment: SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, Carboplatin, and Pemetrexed
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Record updated
- 29 October 2025